Deutsche Bank Aktiengesellschaft Lowers Humana (NYSE:HUM) Price Target to $250.00

Humana (NYSE:HUM) had its price objective lowered by stock analysts at Deutsche Bank Aktiengesellschaft from $349.00 to $250.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has a “hold” rating on the insurance provider’s stock. Deutsche Bank Aktiengesellschaft’s price target would indicate a potential upside of 4.15% from the company’s previous close.

Several other equities analysts also recently weighed in on the company. Oppenheimer dropped their price objective on Humana from $400.00 to $280.00 and set an “outperform” rating for the company in a research note on Thursday. Morgan Stanley started coverage on Humana in a research report on Monday, June 24th. They set an “equal weight” rating and a $374.00 price target for the company. Truist Financial raised their price target on Humana from $355.00 to $400.00 and gave the stock a “hold” rating in a research report on Monday, July 15th. Cantor Fitzgerald reissued a “neutral” rating and set a $395.00 price target on shares of Humana in a research report on Tuesday. Finally, TD Cowen raised their price target on Humana from $396.00 to $407.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. One investment analyst has rated the stock with a sell rating, sixteen have issued a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Humana has an average rating of “Hold” and an average price target of $357.24.

Humana Stock Performance

NYSE HUM opened at $240.03 on Thursday. Humana has a 1-year low of $213.31 and a 1-year high of $530.54. The company has a market capitalization of $28.92 billion, a P/E ratio of 14.95, a PEG ratio of 2.44 and a beta of 0.50. The business has a 50 day moving average price of $337.70 and a 200 day moving average price of $342.42. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.66 and a quick ratio of 1.66.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share for the quarter, beating the consensus estimate of $5.89 by $1.07. Humana had a return on equity of 16.12% and a net margin of 1.53%. The firm had revenue of $29.54 billion during the quarter, compared to the consensus estimate of $28.52 billion. During the same period last year, the business posted $8.94 EPS. Humana’s quarterly revenue was up 10.4% on a year-over-year basis. Sell-side analysts expect that Humana will post 16.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Park Avenue Securities LLC lifted its stake in shares of Humana by 17.3% during the third quarter. Park Avenue Securities LLC now owns 4,857 shares of the insurance provider’s stock worth $1,538,000 after purchasing an additional 718 shares in the last quarter. Czech National Bank lifted its stake in shares of Humana by 6.8% during the third quarter. Czech National Bank now owns 24,527 shares of the insurance provider’s stock worth $7,769,000 after purchasing an additional 1,564 shares in the last quarter. AMF Tjanstepension AB lifted its stake in shares of Humana by 166.8% during the third quarter. AMF Tjanstepension AB now owns 40,051 shares of the insurance provider’s stock worth $12,686,000 after purchasing an additional 25,041 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its stake in shares of Humana by 110.7% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 40,400 shares of the insurance provider’s stock worth $15,095,000 after purchasing an additional 21,225 shares in the last quarter. Finally, University of Texas Texas AM Investment Management Co. lifted its stake in shares of Humana by 1,219.0% during the second quarter. University of Texas Texas AM Investment Management Co. now owns 1,319 shares of the insurance provider’s stock worth $493,000 after purchasing an additional 1,219 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.